Loading...
NU Hospitals Private Limited — Osimertinib Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #2 for Osimertinib · $130.8K export value · DGFT Verified
NU Hospitals Private Limited is the #2 Indian exporter of Osimertinib with $130.8K in export value and 4 verified shipments. NU Hospitals Private Limited holds a 12.0% market share in Osimertinib exports across 1 countries. The company exports 7 pharmaceutical products worth $1.0M across 3 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| BRAZIL | $620.3K | 116 | 63.6% |
| UNITED KINGDOM | $150.0K | 3 | 15.4% |
| MALDIVES | $130.8K | 4 | 13.4% |
| BANGLADESH | $36.4K | 2 | 3.7% |
| LEBANON | $18.6K | 1 | 1.9% |
| SWITZERLAND | $15.0K | 1 | 1.5% |
| SINGAPORE | $4.6K | 2 | 0.5% |
| GREECE | $2 | 1 | 0.0% |
India exports Osimertinib to 8 countries. The top destination is BRAZIL (63.6%), followed by UNITED KINGDOM and MALDIVES.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| INDIRA GANDHI MEMORIAL HOSPITAL | MALDIVES | $130.8K | 4 |
| TO THE CONCERN PERSON | BRAZIL | $125.4K | 16 |
| INCEPTA PHARMACEUTICALS LTD | BANGLADESH | $36.4K | 2 |
| CONCERN PERSON WANILDA DE | BRAZIL | $34.7K | 4 |
| TO THE | BRAZIL | $17.2K | 4 |
| GUILHERME MARTINS DE ALMEIDA | BRAZIL | $17.1K | 2 |
India exported $751.2K worth of Osimertinib through 130 shipments from 15 suppliers to 8 countries, serving 50 buyers globally. NU Hospitals Private Limited contributes $130.8K to this total, accounting for 12.0% of India's Osimertinib exports.
NU Hospitals Private Limited's average Osimertinib shipment value is $32.7K per consignment, based on 4 shipments totaling $130.8K.
NU Hospitals Private Limited ranks #2 among 15 Indian Osimertinib exporters with a 12.0% market share. The top 3 exporters are NIVIRA EXPORTS ($347.1K), NU HOSPITALS PRIVATE LIMITED ($130.8K), IKRIS PHARMA NETWORK PRIVATE LIMITED ($76.3K). NU Hospitals Private Limited processed 4 shipments to 1 destination countries.
What NU Hospitals Private Limited must comply with to export Osimertinib to its top destination countries
Approval Process
Generic registration under RDC 200/2017. ANVISA GMP inspection of Indian facility mandatory before approval.
Timeline: 12–24 months
GMP & Export Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Certificate of Pharmaceutical Product from CDSCO; Import Authorization via SISCOMEX
Note: ANVISA maintains active Indian pharma facility inspection program. Inspection backlog can extend timelines.
Approval Process
Post-Brexit UK Marketing Authorisation via national procedure. Separate from EU approval since January 2021.
Exporters ranked immediately above and below #2 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | NIVIRA EXPORTS | $347.1K | 52 | 1 | $6.7K |
| 2 | NU HOSPITALS PRIVATE LIMITED ★ | $130.8K | 4 | 1 | $32.7K |
| 3 | IKRIS PHARMA NETWORK PRIVATE LIMITED | $76.3K | 17 | 1 | $4.5K |
| 4 | MATSUN EXPORTS | $57.1K | 14 | 1 | $4.1K |
NU Hospitals Private Limited ranks among 15 Indian Osimertinib exporters.
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 64 | 49.2% |
| DELHI AIR | 15 | 11.5% |
| AHEMDABAD AIR ACC (INAMD4) | 10 | 7.7% |
| SAHAR AIR CARGO ACC (INBOM4) | 9 | 6.9% |
| SONAULI LCS | 6 | 4.6% |
| Ahmedabad Air | 6 | 4.6% |
| Bombay Air | 5 | 3.8% |
| TUGLAKABAD ICD | 3 | 2.3% |
NU Hospitals Private Limited also exports these advanced oncology products. Each links to the detailed product page.
NU Hospitals Private Limited exports 7 products worth $1.0M. Beyond Osimertinib, top products include Trastuzumab, Pembrolizumab, Nicotine, Cetuximab, Nivolumab. View the complete NU Hospitals Private Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Osimertinib — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for NU Hospitals Private Limited's Osimertinib exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
NU Hospitals Private Limited
Full Company Profile →
7 products · $1.0M total trade · 3 categories
| TO THE, | BRAZIL | $15.4K | 3 |
| LUIZ FRANCISCO GENRO SCHORN | BRAZIL | $12.8K | 2 |
| MARGARIDA ALVES DE SOUSA | BRAZIL | $12.8K | 2 |
| MARIZETE ALVES DE MORAES | BRAZIL | $12.8K | 2 |
India's Osimertinib is purchased by 50 buyers worldwide. The top buyer is INDIRA GANDHI MEMORIAL HOSPITAL (MALDIVES), followed by TO THE CONCERN PERSON and INCEPTA PHARMACEUTICALS LTD.
Timeline: 12–15 months
GMP & Export Requirements
UK GMP compliance; MHRA inspection of manufacturing site
Manufacturer Import Authorisation (MIA) held by UK importer; Qualified Person (QP) batch release
Note: Post-Brexit: EU GMP certificates no longer automatically valid in UK. Separate MHRA recognition required.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 8+ countries, 50+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for NU Hospitals Private Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Osimertinib. For current shipment-level data, contact TransData Nexus.